OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma

BackgroundPancreatic ductal adenocarcinoma (PDAC) is a type of malignant tumor with a five-year survival rate of less than 10%. Gemcitabine (GEM) is the most commonly used drug for PDAC chemotherapy. However, a vast majority of patients with PDAC develop resistance after GEM treatment.MethodsWe scre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jinsheng Ding, Hui Li, Yang Liu, Yongjie Xie, Jie Yu, Huizhi Sun, Di Xiao, Yizhang Zhou, Li Bao, Hongwei Wang, Chuntao Gao
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Pancreatic ductal adenocarcinoma
OXCT1
gemcitabine
chemoresistance
NF-κB
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/948f63ba82084a768da6ea5f421b1b8d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/948f63ba82084a768da6ea5f421b1b8d

Ejemplares similares